Written by Klarity Editorial Team
Published: Jul 15, 2026

Last updated: July 15, 2026
Good news for West Virginia Aetna members: CVS/Caremark reinstated Zepbound (tirzepatide) to its commercial formularies effective October 1, 2026. If you have Aetna coverage in West Virginia, you may now be able to access Zepbound with a prior authorization through your CVS/Caremark pharmacy benefit. See if Klarity’s licensed providers can help you start the process today.
Weight loss treatment has changed dramatically in 2026. GLP-1 receptor agonist medications like Wegovy and Zepbound have reshaped what medically supervised weight management looks like — and what insurance may cover. If you have Aetna health insurance in West Virginia, this guide explains what weight loss treatments Aetna may cover, how CVS/Caremark manages the pharmacy benefit, what prior authorization requirements may apply, and how West Virginia regulations affect your rights.
Aetna commercial plans in West Virginia may cover medically supervised weight loss treatment, though covered services and medications vary by plan. Weight loss coverage is governed by the Affordable Care Act’s Essential Health Benefits (ACA EHB) framework and ERISA for self-funded employer plans — not by West Virginia’s mental health parity statute (W. Va. Code § 33-25-8r), which applies only to mental health and substance use disorder services.
Weight loss treatments that Aetna may cover for eligible West Virginia members typically include:
Important: Coverage depends on your specific Aetna plan, whether your employer is self-funded or fully insured, and the medical necessity criteria your plan applies. Always verify your specific benefits before beginning treatment. Explore Klarity’s weight loss program to learn about your options.
Aetna uses CVS/Caremark as its pharmacy benefit manager (PBM) for most West Virginia commercial plans. CVS/Caremark reinstated Zepbound (tirzepatide injection) to its commercial formularies effective October 1, 2026 — a significant development for West Virginia Aetna members who may have been told Zepbound was not covered under their plan. Below is the current CVS/Caremark commercial formulary structure for weight loss medications in 2026:
| Medication | Generic Name | Tier | PA Required? | Notes |
|---|---|---|---|---|
| Wegovy | Semaglutide injection (weight loss dose) | Tier 3–4 | Yes | BMI ≥30, or ≥27 with weight-related comorbidity; lifestyle documentation may be required |
| Zepbound | Tirzepatide injection | Tier 3–4 | Yes | Reinstated Oct 1 2026; BMI ≥30, or ≥27 with comorbidity; verify with plan |
| Saxenda | Liraglutide injection (weight loss dose) | Tier 3–4 | Yes | PA required; BMI criteria; may require step therapy before Wegovy/Zepbound on some plans |
| Contrave | Naltrexone/bupropion ER | Tier 2–3 | PA likely | Oral medication; BMI criteria apply; PA requirements vary by plan |
| Qsymia | Phentermine/topiramate ER | Tier 2–3 | Yes | Schedule IV controlled substance; EPCS applies (see below); REMS program; BMI criteria |
| Orlistat (generic) | Orlistat | Tier 1–2 | No | Oral lipase inhibitor; OTC strength also available without prescription |
| Alli (OTC orlistat) | Orlistat 60 mg | Not covered | N/A | OTC strength typically not covered; prescription 120 mg may be covered |
| Phentermine (generic) | Phentermine HCl | Tier 1–2 | No for short-term | Schedule IV controlled substance; EPCS applies; short-term use (typically ≤12 weeks); quantity limits apply |
| Mounjaro | Tirzepatide injection (diabetes indication) | Tier 3–4 | Yes | Covered for T2DM indication; if prescribed off-label for weight loss only, coverage may be denied |
| Ozempic / Rybelsus | Semaglutide (diabetes indication) | Tier 3–4 | Yes | Covered for T2DM indication; off-label weight loss use may not be covered separately from Wegovy |
Formulary tiers and prior authorization criteria are subject to change. Verify current coverage with Aetna or CVS/Caremark before filling a prescription.
Zepbound (tirzepatide) was previously removed from some CVS/Caremark commercial formularies. As of October 1, 2026, CVS/Caremark has reinstated Zepbound on commercial formularies. For West Virginia Aetna members, this means Zepbound may now be accessible through the pharmacy benefit with prior authorization — rather than requiring appeals, exceptions, or manufacturer coupons as a workaround. If you were previously denied Zepbound coverage, it is worth re-requesting a coverage determination or speaking with your prescribing provider about submitting a new prior authorization under the reinstated formulary status.
West Virginia imposes electronic prescribing requirements under W. Va. Code § 60A-4-403a, which applies to all controlled substances — a broader mandate than most states, which typically apply EPCS only to Schedule II drugs. For weight loss medications, this means:
In practical terms, EPCS compliance is handled at the prescriber level. Patients do not need to take any action related to EPCS — it affects how your provider transmits the prescription, not whether you can fill it. Klarity’s licensed providers are EPCS-compliant and can electronically prescribe Schedule IV weight loss medications for eligible West Virginia patients.
Most prescription weight loss medications covered by Aetna/CVS/Caremark require prior authorization. Typical prior authorization criteria for GLP-1 weight loss medications (Wegovy, Zepbound) include:
West Virginia Senate Bill 267 (2024) requires all prior authorization requests for Aetna commercial fully insured plans in West Virginia to be submitted electronically via Availity. Paper PA forms are no longer accepted. Your prescribing provider or their office staff will submit the PA through the Availity portal (availity.com) using your Aetna plan information.
Typical PA timeline expectations:
West Virginia’s mental health parity statute, W. Va. Code § 33-25-8r et seq., requires commercial fully insured health plans to cover mental health and substance use disorder services on terms no more restrictive than medical/surgical benefits. This parity law does not apply to weight loss treatment — weight loss is not classified as a mental health or substance use disorder condition under the statute.
Instead, weight loss benefit coverage for West Virginia Aetna members is governed by:
If you believe your plan has improperly denied weight loss coverage, you have the right to appeal. For fully insured plans, the West Virginia Insurance Commissioner (1-888-879-9842) can assist with complaints. For self-funded ERISA plans, the U.S. Department of Labor handles benefit claim disputes.
Aetna offers several plan structures in West Virginia for commercial members. Understanding your plan type helps you anticipate how weight loss referrals and authorizations work:
Before scheduling a weight loss consultation or starting a prescription, confirm your specific coverage by taking these steps:
Klarity Health connects West Virginia residents with licensed, board-certified providers who specialize in medically supervised weight management. Our providers can evaluate whether GLP-1 medications like Wegovy or Zepbound may be clinically appropriate for you, assist with prior authorization submissions through your Aetna/CVS/Caremark plan, and provide ongoing monitoring and support for your weight loss program.
Klarity’s providers are EPCS-compliant in West Virginia and can electronically prescribe Schedule IV medications including phentermine and Qsymia where appropriate. With 2,000+ licensed providers in our network, you can often schedule an appointment within days — without needing a referral in most plan types.
See if Klarity’s weight loss program may be right for you. Coverage varies by plan — we’ll help you understand your options.
Zepbound (tirzepatide) was reinstated to CVS/Caremark commercial formularies effective October 1, 2026. West Virginia Aetna members using CVS/Caremark as their pharmacy benefit manager may now be able to access Zepbound with prior authorization, subject to BMI and medical necessity criteria. If you were previously denied Zepbound, it is worth requesting a new PA determination under the updated formulary. Verify your specific plan’s coverage with CVS/Caremark at 1-800-552-8159.
Wegovy (semaglutide injection, weight loss dose) is typically placed at Tier 3–4 on CVS/Caremark commercial formularies and typically requires prior authorization. PA criteria generally include a BMI of 30 or greater, or BMI of 27 or greater with a weight-related comorbidity. Coverage depends on your specific Aetna plan — verify with Aetna at 1-800-872-3862 or CVS/Caremark at 1-800-552-8159.
Referral requirements depend on your plan type. Aetna Choice POS II and Select (HMO-based) plans typically require a referral from your primary care physician for specialist weight management consultations. Aetna Open Choice PPO members generally do not need a referral. If you see a Klarity provider, you can typically schedule directly through our platform — though we recommend confirming your specific plan’s requirements with Aetna at 1-800-872-3862.
No. West Virginia’s mental health parity law, W. Va. Code § 33-25-8r et seq., applies specifically to mental health and substance use disorder services. Weight loss treatment is not covered by this statute. Weight loss benefit coverage is governed by the ACA Essential Health Benefits framework, ERISA for self-funded employer plans, and your specific plan’s benefit design.
Yes. Phentermine is a Schedule IV controlled substance. Under W. Va. Code § 60A-4-403a, all controlled substances — including Schedule IV drugs — must be prescribed electronically in West Virginia. This means your provider must transmit the prescription electronically to your pharmacy. Qsymia (phentermine/topiramate ER), also Schedule IV, additionally requires REMS enrollment. GLP-1 medications (Wegovy, Zepbound, Saxenda) are not controlled substances and do not require electronic prescribing under WV law.
If your prior authorization for a weight loss medication is denied, you have the right to appeal. For fully insured Aetna plans in West Virginia, WV SB 267 requires PA submissions via Availity. You may file an internal appeal within 60 days of the denial. If the internal appeal is denied, you can request an external independent review. For fully insured plans, the West Virginia Insurance Commissioner at 1-888-879-9842 can provide assistance. Your prescribing provider may also be able to request a peer-to-peer review with Aetna’s medical director.
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Insurance coverage for weight loss treatment varies by plan, employer, and individual circumstances. Always verify your specific benefits with Aetna and CVS/Caremark before beginning treatment or filling a prescription. Coverage described above reflects general CVS/Caremark commercial formulary patterns and Aetna plan structures as of July 2026; individual plan coverage may differ. Klarity Health does not guarantee insurance coverage for any treatment.
Find the right provider for your needs — select your state to find expert care near you.